Program
ribupatide
Also written as “HRS9531”, “HRS9531 injection” and “HRS9531 Tablet”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic · Atherosclerosis · Fatty Liver, led by 2 companies.
Drug pageRibupatide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 3214 open or running | phase 3since Apr 30, 2024 | Nov 29, 2021 | Dec 2026phase 3 · NCT06994650 |
| Kailera | 65 open or running | phase 3since Dec 9, 2025 | Jun 23, 2025 | May 2027phase 2 · NCT07458269 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
Ribupatide
, phase 4, as of Jul 31, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseKailera licensed it from Hengrui, for everywhere outside Greater China.Agreed May 2024 · Source: Kailera Therapeutics (release), Oct 1, 2024
History and studies of Kailera only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 2024Kailera licensed it from HengruiLicenseEverywhere outside Greater China · agreed · Kailera Therapeutics (release)
- Jun 23, 2025First study: phase 1 study in OverweightFirst studyNCT07044401 · 51 enrolled · United States
- Jul 10, 2025Named ribupatideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HRS9531
- Dec 9, 20253 phase 3 studies in ObesityPhase 3 reachedNCT07284979, NCT07284901, NCT07284875
- Mar 3, 2026Phase 2 study in ObesityNCT07458269 · 264 enrolled · United States
- Aug 25, 2026Phase 1 study in Kidney Failure, ChronicNCT07793929 · 32 planned · United States
Ahead
- May 2027Primary completion: phase 2 study in ObesityNCT07458269
- Feb 2028Primary completion: phase 3 study in ObesityNCT07284875
- Feb 8, 2028Primary completion: phase 1 study in Kidney Failure, ChronicNCT07793929
- Mar 2028Primary completion: phase 3 study in ObesityNCT07284979
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 Kailera leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07793929Kidney Failure, Chronic · United States | 1 | Recruiting | Feb 8, 2028 | 32 |
| NCT07458269Obesity · United States | 2 | Active, not recruiting | May 2027 | 264 |
| NCT07284979Obesity · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Mar 2028 | 1,270 |
| NCT07284901Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 27, 2028 | 1,270 |
| NCT07284875Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2028 | 2,530 |
| NCT07044401Overweight · United States | 1 | Completed | Nov 13, 2025 | 51 |
How it is read
Names in the registry
- “HRS9531”, 16 entries
- “HRS9531 injection”, 14 entries
- “HRS9531 Tablet”, 9 entries
- “HRS9531 Injection”, 6 entries
- “Ribupatide”, 5 entries
Codes read as this program: HRS9531.
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 12 studies
- Kidney Failure, Chronic, 1 study
- Atherosclerosis, 1 study
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.